Literature DB >> 20840535

Expression and function of the K+ channel KCNQ genes in human arteries.

Fu Liang Ng1, Alison J Davis, Thomas A Jepps, Maksym I Harhun, Shuk Yin Yeung, Andrew Wan, Marcus Reddy, David Melville, Antonio Nardi, Teck K Khong, Iain A Greenwood.   

Abstract

BACKGROUND AND
PURPOSE: KCNQ-encoded voltage-gated potassium channels (K(v) 7) have recently been identified as important anti-constrictor elements in rodent blood vessels but the role of these channels and the effects of their modulation in human arteries remain unknown. Here, we have assessed KCNQ gene expression and function in human arteries ex vivo. EXPERIMENTAL APPROACH: Fifty arteries (41 from visceral adipose tissue, 9 mesenteric arteries) were obtained from subjects undergoing elective surgery. Quantitative RT-PCR experiments using primers specific for all known KCNQ genes and immunohistochemsitry were used to show K(v) 7 channel expression. Wire myography and single cell electrophysiology assessed the function of these channels. KEY
RESULTS: KCNQ4 was expressed in all arteries assessed, with variable contributions from KCNQ1, 3 and 5. KCNQ2 was not detected. K(v) 7 channel isoform-dependent staining was revealed in the smooth muscle layer. In functional studies, the K(v) 7 channel blockers, XE991 and linopirdine increased isometric tension and inhibited K(+) currents. In contrast, the K(v) 7.1-specific blocker chromanol 293B did not affect vascular tone. Two K(v) 7 channel activators, retigabine and acrylamide S-1, relaxed preconstricted arteries, actions reversed by XE991. K(v) 7 channel activators also suppressed spontaneous contractile activity in seven arteries, reversible by XE991. CONCLUSIONS AND IMPLICATIONS: This is the first study to demonstrate not only the presence of KCNQ gene products in human arteries but also their contribution to vascular tone ex vivo. LINKED ARTICLE: This article is commented on by Mani and Byron, pp. 38-41 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476-5381.2010.01065.x.
© 2010 The Authors. British Journal of Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20840535      PMCID: PMC3012405          DOI: 10.1111/j.1476-5381.2010.01027.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991.

Authors:  H S Wang; B S Brown; D McKinnon; I S Cohen
Journal:  Mol Pharmacol       Date:  2000-06       Impact factor: 4.436

2.  Molecular and functional characterization of Kv7 K+ channel in murine gastrointestinal smooth muscles.

Authors:  Thomas A Jepps; Iain A Greenwood; James D Moffatt; Kenton M Sanders; Susumu Ohya
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-23       Impact factor: 4.052

Review 3.  Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention.

Authors:  Alexander R Mackie; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2008-08-06       Impact factor: 4.436

4.  Expression profile and characterisation of a truncated KCNQ5 splice variant.

Authors:  Shuk Yin M Yeung; Wienke Lange; Michael Schwake; Iain A Greenwood
Journal:  Biochem Biophys Res Commun       Date:  2008-05-05       Impact factor: 3.575

Review 5.  New tricks for old dogs: KCNQ expression and role in smooth muscle.

Authors:  Iain A Greenwood; Susumu Ohya
Journal:  Br J Pharmacol       Date:  2009-04       Impact factor: 8.739

6.  Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance.

Authors:  Alexander R Mackie; Lioubov I Brueggemann; Kyle K Henderson; Aaron J Shiels; Leanne L Cribbs; Karie E Scrogin; Kenneth L Byron
Journal:  J Pharmacol Exp Ther       Date:  2008-02-13       Impact factor: 4.030

7.  Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents.

Authors:  Sym Yeung; M Schwake; V Pucovský; Ia Greenwood
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

8.  Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity.

Authors:  S Y M Yeung; V Pucovský; J D Moffatt; L Saldanha; M Schwake; S Ohya; I A Greenwood
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

9.  KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle.

Authors:  Shreena Joshi; Vojtech Sedivy; Daniel Hodyc; Jan Herget; Alison M Gurney
Journal:  J Pharmacol Exp Ther       Date:  2009-01-16       Impact factor: 4.030

10.  Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.

Authors:  R J Porter; A Partiot; R Sachdeo; V Nohria; W M Alves
Journal:  Neurology       Date:  2007-04-10       Impact factor: 9.910

View more
  63 in total

1.  Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy.

Authors:  Lioubov I Brueggemann; Priyanka P Kakad; Robert B Love; Julian Solway; Maria L Dowell; Leanne L Cribbs; Kenneth L Byron
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-30       Impact factor: 5.464

2.  Vascular KCNQ channels in humans: the sub-threshold brake that regulates vascular tone?

Authors:  Bharath K Mani; Kenneth L Byron
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

3.  KV7 Channel Pharmacological Activation by the Novel Activator ML213: Role for Heteromeric KV7.4/KV7.5 Channels in Guinea Pig Detrusor Smooth Muscle Function.

Authors:  Aaron Provence; Damiano Angoli; Georgi V Petkov
Journal:  J Pharmacol Exp Ther       Date:  2017-10-30       Impact factor: 4.030

4.  Activation of Kv 7 channels as a novel mechanism for NO/cGMP-induced pulmonary vasodilation.

Authors:  Gema Mondéjar-Parreño; Javier Moral-Sanz; Bianca Barreira; Alicia De la Cruz; Teresa Gonzalez; Maria Callejo; Sergio Esquivel-Ruiz; Daniel Morales-Cano; Laura Moreno; Carmen Valenzuela; Francisco Perez-Vizcaino; Angel Cogolludo
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

5.  KV 7 channels are involved in hypoxia-induced vasodilatation of porcine coronary arteries.

Authors:  E R Hedegaard; B D Nielsen; A Kun; A D Hughes; C Krøigaard; S Mogensen; V V Matchkov; O Fröbert; U Simonsen
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

6.  Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370.

Authors:  T A Jepps; B H Bentzen; J B Stott; O V Povstyan; K Sivaloganathan; W Dalby-Brown; I A Greenwood
Journal:  Br J Pharmacol       Date:  2014-08-14       Impact factor: 8.739

7.  Chemical control of metabolically-engineered voltage-gated K+ channels.

Authors:  Zhengmao Hua; Anatoli Lvov; Trevor J Morin; William R Kobertz
Journal:  Bioorg Med Chem Lett       Date:  2011-04-28       Impact factor: 2.823

8.  Cardiovascular responses to retigabine in conscious rats--under normotensive and hypertensive conditions.

Authors:  L V Fretwell; J Woolard
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

9.  Differential protein kinase C-dependent modulation of Kv7.4 and Kv7.5 subunits of vascular Kv7 channels.

Authors:  Lioubov I Brueggemann; Alexander R Mackie; Leanne L Cribbs; Jessica Freda; Abhishek Tripathi; Matthias Majetschak; Kenneth L Byron
Journal:  J Biol Chem       Date:  2013-12-02       Impact factor: 5.157

Review 10.  One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.

Authors:  T A Jepps; S P Olesen; I A Greenwood
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.